Transforming growth factor beta

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

Retrieved on: 
Monday, April 8, 2024
Transforming growth factor beta, Partnership, Acquisition, Cancer, Protein kinase, Windtree Therapeutics, Lung cancer, Note, Therapy, Protein kinase C, PKC, Skin, Protein kinase inhibitor, Security (finance)

The Company also completed a $1.5 million convertible note bridge financing.

Key Points: 
  • The Company also completed a $1.5 million convertible note bridge financing.
  • The acquired Varian asset platform is a novel, potential high-potency, specific, aPKCi with possible broad use in oncology as well as certain rare malignant diseases.
  • “Completion of the Varian asset acquisition and the bridge financing represents a potentially transformative next step for Windtree.
  • Additional details are available by reading the Company’s Current Report on Form 8-K relating to the Varian asset acquisition and senior convertible note bridge financing, which was filed with the Securities and Exchange Commission on April 8, 2024.

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Retrieved on: 
Wednesday, March 27, 2024
Transforming growth factor beta, Eli Lilly, Atrophy, DVM, Obesity, Drug discovery, Exercise, Partnership, Patient, SAN, EDT, Learning, Entrepreneurship, IND, Antibody, Drug development, PIPE, Pharmaceutical industry

BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (“AstralBio”) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.

Key Points: 
  • Yesterday, iBio announced the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional investors.
  • The company will use a portion of the net proceeds to support new partnerships, such as this collaboration with AstralBio.
  • The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio’s ability to create antibodies against hard-to-drug targets with AstralBio’s significant biologics experience and drug development expertise.
  • iBio has the exclusive option to license three (3) cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise.

Linkage of Cancer and Lupus in Gliomas Patients

Retrieved on: 
Monday, March 25, 2024
CD86, OS, TME, Gene, Transforming growth factor beta, CD68, Survival, LGG, Ligand, TGFB2, CD276, IDH, STAT1, Inflammation, Central nervous system, Patient, RNA, Tumor microenvironment, Cancer, Messenger, Macrophage, SLE, Expression, TAM, Treatment, Neoplasm, IRF5, Therapy, TGF, IRF1, TGFB, OTCQB, Demethylation, Vaccine

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).
  • Understanding the role of IRF5 in both SLE and cancer opens an avenue for targeting IRF5 or its downstream pathways.
  • LGG patients expressing high levels of TGFB2 and IFNGR2 are over-represented in IDH wild-type tumor samples, suggesting that TGFB2 and IFNGR2 mRNA can be therapeutically targeted in these high-risk patients.
  • Therefore, to improve OS in LGG patients, combination therapies must target TGFB2 and IFN-γ activation (via IRF5 inhibition) or immune therapies targeted against CD276/B7-H3

Kanazawa University research: Genetic switches in tumor development

Retrieved on: 
Thursday, November 9, 2023
Transition, Neoplasm, Triple test, Organoid, TGF, Colorectal cancer, Cancer, Differentiable function, Environment, Receptor (biochemistry), Growth, Malignancy, Kanazawa University, Transforming growth factor beta, Cytokine, EMT, Cancer research, Gene, Blood, Infection, Mutation, Vaccine, Medical imaging

KANAZAWA, Japan, Nov. 9, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway.

Key Points: 
  • KANAZAWA, Japan, Nov. 9, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway.
  • However, it has been established that a process known as transforming growth factor ß (TGF-ß) signaling plays a role in both tumor suppression and progression.
  • Now, Masanobu Oshima from Kanazawa University and colleagues have studied the precise genetic conditions underlying the outcome of TGF-ß signaling.
  • In certain cancer cells treated with activin, the researchers noted that the partial EMT is induced with tumor aggressiveness and development.

Kanazawa University research: Genetic switches in tumor development

Retrieved on: 
Thursday, November 9, 2023
Transition, Neoplasm, Triple test, Organoid, TGF, Colorectal cancer, Cancer, Differentiable function, Environment, Receptor (biochemistry), Growth, Malignancy, Kanazawa University, Transforming growth factor beta, Cytokine, EMT, Cancer research, Gene, Blood, Infection, Mutation, Vaccine, Medical imaging

KANAZAWA, Japan, Nov. 9, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway.

Key Points: 
  • KANAZAWA, Japan, Nov. 9, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway.
  • However, it has been established that a process known as transforming growth factor ß (TGF-ß) signaling plays a role in both tumor suppression and progression.
  • Now, Masanobu Oshima from Kanazawa University and colleagues have studied the precise genetic conditions underlying the outcome of TGF-ß signaling.
  • In certain cancer cells treated with activin, the researchers noted that the partial EMT is induced with tumor aggressiveness and development.

Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, May 9, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Gene, ACET, Bio, Design, CD20, NHL, Cancer, Holocene, Research and development, CAR, Transforming growth factor beta, CDMO, Patient, Administration, Cell, American Society of Gene and Cell Therapy, R, FDA, IND, Society, Safety, Pharmaceutical industry, Vaccine

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023.
  • “We are excited about the continued clinical progress of our lead asset ADI-001,” said Chen Schor, President and Chief Executive Officer of Adicet.
  • The Company is preparing to initiate its first potential pivotal study with ADI-001 in the fourth quarter of 2023.
  • Financial Results for First Quarter 2023:
    Research and Development (R&D) Expenses: R&D expenses were $26.8 million for the three months ended March 31, 2023, compared to $13.5 million during the same period in 2022.

Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, April 17, 2023
PK, AACR, Phosphorylation, SMAD, TGF beta 1, NK, Doctor of Philosophy, Transforming growth factor beta, Cancer, TME, Mouse, Poster, Neoplasm, Corbus, TGI, M1, Breast cancer, Vaccine

NORWOOD, Mass., April 17, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced details of new pre-clinical data on CRB-601, its avβ8 blocking antibody, presented as a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, held April 14-19, 2023 in Orlando, FL.

Key Points: 
  • NORWOOD, Mass., April 17, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced details of new pre-clinical data on CRB-601, its avβ8 blocking antibody, presented as a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, held April 14-19, 2023 in Orlando, FL.
  • In addition, the impact on TGFβ pathway signaling and tumor immune cell population are also presented.
  • Tumor growth was evaluated in mice bearing orthotopically implanted murine breast cancer EMT6 or colon cancer MC38 and treated with CRB-601.
  • Together this data reinforces the potential of this new approach in blocking activation of TGFb locally in the TME."

aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution

Retrieved on: 
Tuesday, March 21, 2023
Pressure, Drug development, Small RNA, Transforming growth factor beta, Fibroblast, Cell, DARS, ATyr Pharma, Extracellular matrix, Fibrosis, Biology, Poster, Pharmaceutical industry, LTBP1, Research

SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Leslie A. Nangle, Ph.D., Vice President, Research, will present findings from its platform in an oral presentation and poster at the Keystone Symposia on Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies, which is scheduled to take place March 19 – 23 in Banff, Alberta, Canada.

Key Points: 
  • ATYR0101 was found to bind to human fibroblasts and extracellular matrix deposited by fibroblasts via novel binding of latent transforming growth factor beta binding protein 1 (LTBP1).
  • LTBP1 is an extracellular matrix protein and key regulator of transforming growth factor beta (TGF-β), a central player in the pathogenesis of fibrotic diseases.
  • aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 9, 2023
Transforming growth factor beta, EST, Medicine, IND, ATyr Pharma, Kyorin, European Medicines Agency, Conference, Clinical trial, Sarcoidosis, ILD, DC, Diagnosis, Interest, Food and Drug Administration, Systemic scleroderma, SAN, Committee, D, EMA, Fibrosis, Patient, FDA, Research, PST, Investigational New Drug, European Patent Office, Disease, American Thoracic Society, Food, Small RNA, European Patent Convention, Patent, Civil service commission, ATS, European Commission, Exercise, Investment, DARS, Scleroderma, Tokyo International Conference on African Development, Safety, Pharmaceutical industry, LTBP1, EU

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.
  • This achievement triggered a $10.0 million milestone payment to aTyr in the fourth quarter.
  • Based on the Company’s current operational plans and existing cash, aTyr believes the Company’s cash runway will extend into 2026.
  • Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .

Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

Retrieved on: 
Monday, March 6, 2023
ADC, Multiple myeloma, Bone marrow, MBA, AstraZeneca, Transforming growth factor beta, TGF, Takeda Oncology, Kidney, Durvalumab, Drug discovery, Mab, California Pacific Medical Center, Pfizer, Compugen (company), Carcinoma, University, Strategic planning, University of California, San Diego Performance-Based Skills Assessment, Peking Union Medical College Hospital, SAN, Axitinib, Pharmaceutical industry, BeiGene, Corbus

NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors.

Key Points: 
  • NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors.
  • "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus.
  • Dr. Ben received his medical degree from Norman Bethune College of Medicine and his MBA from the University of California, San Diego.
  • "I look forward to working with the talented Corbus team to develop CRB-701 and CRB-601 and realize their potential."